Following the LEADER – why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes

Journal of Diabetes and its Complications

Volumn 31, Issue 2, 2017, Pages 517-519

  Kosiborod, Mikhail ^a  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; LIXISENATIDE; PIOGLITAZONE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CARDIOTONIC AGENT; GLUCAGON LIKE PEPTIDE 1;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); FOLLOW UP; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MANAGED CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; AGONISTS; COMPLICATION; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; METABOLISM; PERSONALIZED MEDICINE;

CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; PRECISION MEDICINE; RISK FACTORS;

EID: 85006241166     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2016.08.017     Document Type: Review

References (19)

1. Cushman, WC, Evans, GW, Byington, RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. The New England Journal of Medicine 362 (2010), 1575–1585.
2. Duckworth, W, Abraira, C, Moritz, T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine 360 (2009), 129–139.
3. Gerstein, HC, Miller, ME, Byington, RP, et al. Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine 358 (2008), 2545–2559.
4. Gerstein, HC, Miller, ME, Genuth, S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. The New England Journal of Medicine 364 (2011), 818–828.
5. Ginsberg, HN, Elam, MB, Lovato, LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. The New England Journal of Medicine 362 (2010), 1563–1574.
6. Hayward, RA, Reaven, PD, Wiitala, WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine 372 (2015), 2197–2206.
7. Holman, RR, Peterson, ED, Sitagliptin and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine, 373, 2015, 2479.
8. Holman, RR, Paul, SK, Bethel, MA, Matthews, DR, Neil, HA, 10-year follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine 359 (2008), 1577–1589.
9. Inzucchi, SE, Bergenstal, RM, Buse, JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38 (2015), 140–149.
10. Kernan, WN, Viscoli, CM, Furie, KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. The New England Journal of Medicine 374 (2016), 1321–1331.
11. Marso, SP, Daniels, GH, Brown-Frandsen, K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine 375 (2016), 311–322.
12. Orchard, TJ, Nathan, DM, Zinman, B, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 313 (2015), 45–53.
13. Patel, A, MacMahon, S, Chalmers, J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine 358 (2008), 2560–2572.
14. Pfeffer, MA, Claggett, B, Diaz, R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. The New England Journal of Medicine 373 (2015), 2247–2257.
15. Scirica, BM, Bhatt, DL, Braunwald, E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England Journal of Medicine 369 (2013), 1317–1326.
16. Wanner, C, Inzucchi, SE, Lachin, JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. The New England Journal of Medicine 375 (2016), 323–334.
17. White, WB, Cannon, CP, Heller, SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. The New England Journal of Medicine 369 (2013), 1327–1335.
18. Wing, RR, Bolin, P, Brancati, FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. The New England Journal of Medicine 369 (2013), 145–154.
19. Zinman, B, Wanner, C, Lachin, JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine 373 (2015), 2117–2128.